Amivantamab (JNJ-61186372), another bispecific antibody targeting both EGFR and MET, was designed with an intention to treat patients with EGFR exon20ins-mutated NSCLC who currently have limited treatment options (163, 164). Here, EGFR is linked to non-small cell lung carcinoma.